Revelation Biosciences, Inc. (REVB) Sets 1-for-7 Reverse Split Effective Oct 20, 2026

Revelation Biosciences (REVB) will execute a 1-for-7 reverse stock split on Oct 20, 2026, to meet Nasdaq's minimum bid price requirement. The company aims to comply with listing standards, with shares trading under a new CUSIP post-split.

Original reporting
Published Oct 16, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 1:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Revelation Biosciences, Inc. (REVB) Sets 1-for-7 Reverse Split Effective Oct 20, 2026 — source image
Decision brief

The 30-second read

$REVBNeutralMed
01

Why it matters

The split could temporarily boost the share price, but long‑term performance hinges on upcoming trial data or financing.

02

Market read

A compliance‑driven corporate action with modest short‑term trading relevance for REVB holders.

03

What to watch

Future clinical or financing milestones will be needed to sustain any price gains post‑split.

Relevance 5/10Novelty 6/10Timing: effective Oct 20, 2026 (pre‑market)

Background

Revelation Biosciences is a small‑cap biotech currently below Nasdaq's $1 minimum bid price, prompting the reverse split.

Company-level read

Ticker impact

$REVBNeutralHigh confidence
Context

Announcement of a 1-for-7 reverse stock split to regain Nasdaq minimum bid price compliance.

Expected impact

likely modest upward pressure as the post‑split price meets compliance thresholds

Evidence & confidence

Reverse splits are typically viewed as a compliance move; the market may price in a short‑term bounce but long‑term impact depends on subsequent milestones.

Market effects

May signal compliance pressure for other small‑cap biotech stocks on Nasdaq.

Limited to U.S. biotech sector; no broader regional effect.

Minimal global impact; primarily a micro‑cap corporate action.

Counterpoint

Some investors may view the split as a red flag and short the stock despite compliance intent.

Key entities

  • Revelation Biosciences, Inc.

    Biotech firm executing a reverse split to meet Nasdaq listing standards.

Related articles

$REVBLow

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 SAN DIEGO – November 5, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developi

$REVBMedAI 8/10

Revelation Aiming for Paradigm Shift in Kidney Disease Care

Revelation Biosciences (REVB) is developing Gemini, a drug candidate for acute and chronic kidney disease, post-surgical infections, and severe burns. The company plans to launch a Phase 2/3 study for acute kidney injury later this year, with completion expected in about two years. CEO James Rolke highlights Gemini's potential to reduce inflammation and prevent scar tissue, citing positive pre-clinical and early clinical results. Revelation aims to submit Gemini for FDA approval if the study mee

$REVBMed

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 SAN DIEGO – August 6, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innov

$SPGIMed

S&P Global Announces Pricing of Public Offering of $750,000,000 Senior Notes due 2031, $600,000,000 Senior Notes due 2034 and $650,000,000 Senior Notes due 2036

S&P Global (NYSE: SPGI) priced a public offering of $750M, $600M, and $650M in senior notes due 2031, 2034, and 2036, respectively. The notes were priced at yields of 5.635%, 5.814%, and 6.001%. Proceeds will be used for general corporate purposes, including possible acquisitions or debt repayment. The offering is expected to close on November 18, 2026, subject to conditions.

$TPBMedAI 8/10

Why Turning Point Brands Stock Got Socked Today

Turning Point Brands (NYSE:TPB) stock fell 11% after filing a mixed shelf registration with the SEC, indicating plans to raise capital. The company registered various securities, including common and preferred stock, for potential sale. Proceeds will be used for general corporate purposes. Shelf registrations often concern investors due to potential dilution or increased debt.